CASCINU, STEFANO
 Distribuzione geografica
Continente #
EU - Europa 1.370
NA - Nord America 1.080
AS - Asia 462
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 11
OC - Oceania 3
AF - Africa 1
Totale 2.938
Nazione #
US - Stati Uniti d'America 1.076
SE - Svezia 750
SG - Singapore 337
RU - Federazione Russa 290
IT - Italia 155
FI - Finlandia 82
CN - Cina 75
DE - Germania 35
IE - Irlanda 25
IN - India 18
IR - Iran 11
ES - Italia 9
EU - Europa 9
JP - Giappone 9
FR - Francia 8
BR - Brasile 7
GB - Regno Unito 5
AR - Argentina 4
CA - Canada 4
AU - Australia 3
NL - Olanda 3
PH - Filippine 3
VN - Vietnam 3
A1 - Anonimo 2
PT - Portogallo 2
AL - Albania 1
BD - Bangladesh 1
BE - Belgio 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
HK - Hong Kong 1
ID - Indonesia 1
IL - Israele 1
MK - Macedonia 1
PK - Pakistan 1
PL - Polonia 1
SA - Arabia Saudita 1
Totale 2.938
Città #
Lawrence 315
Princeton 314
Singapore 189
Moscow 135
New York 112
Helsinki 82
Ashburn 62
Boardman 56
Shanghai 56
Milan 28
Dublin 25
Los Angeles 15
Rome 13
Washington 8
Seattle 6
Tokyo 5
Borås 4
Martinez 4
Oria 4
Pescara 4
Pune 4
Verona 4
Hanoi 3
Hanover 3
Hyderabad 3
London 3
Mumbai 3
San Francisco 3
Amsterdam 2
Ancona 2
Beijing 2
Brasília 2
Brighton 2
Castelfranco Emilia 2
Cerreto Guidi 2
Chiyoda-ku 2
Council Bluffs 2
Florence 2
Foggia 2
Genoa 2
Harwich 2
Kish 2
Lisbon 2
Lucca 2
Ludhiana 2
Lyon 2
Manila 2
Messina 2
Modena 2
Monza 2
Mountain View 2
New Haven 2
Paris 2
Redwood City 2
Rende 2
Rimini 2
Rockville 2
Rubano 2
San Fernando de Henares 2
Sesto San Giovanni 2
St Petersburg 2
Toronto 2
Trieste 2
Turin 2
Verdellino 2
Visakhapatnam 2
Yekaterinburg 2
Aalter 1
Aioicho 1
Alba 1
Andover 1
Ann Arbor 1
Athis-mons 1
Aversa 1
Berlin 1
Bhubaneswar 1
Bologna 1
Bom Despacho 1
Boston 1
Brisbane 1
Buccinasco 1
Chivasso 1
Clifton 1
Dallas 1
Dalmine 1
Darjeeling 1
Dijon 1
Geislingen an der Steige 1
Gliwice 1
Goala Bazar 1
Hamm 1
Henderson 1
Hung Hom 1
Jalandhar 1
Karlsruhe 1
Kashan 1
Kolkata 1
Leawood 1
Makassar 1
Marche 1
Totale 1.574
Nome #
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 41
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 28
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 28
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 27
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 27
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 20
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial 19
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 19
BRAF-mutated colorectal cancer: Clinical and molecular insights 19
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 19
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 19
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 18
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 18
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 18
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 18
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 18
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 18
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 17
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 17
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 17
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 17
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 17
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 17
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 17
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 16
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 16
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 16
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 16
Dabrafenib-trametinib combination in 'field-practice': An Italian experience 16
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 16
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 16
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 16
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 16
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 16
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 16
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 16
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 15
Anal cancer: from an orphan disease to a curable malignancy? 15
Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials 15
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (Targeted Oncology, (2020), 15, 1, (115-126), 10.1007/s11523-020-00698-x) 15
5-Fluorouracil pharmacogenomics: still rocking after all these years? 15
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 15
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 14
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 14
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 14
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 14
Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses 14
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 14
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 14
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 14
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients 14
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 14
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 14
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 14
Cholangiocarcinoma: new perspectives for new horizons 14
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 14
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 14
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 13
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 13
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 13
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 13
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 13
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 13
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 13
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 13
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 13
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis 13
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice 13
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants 13
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 13
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 12
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 12
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 12
Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer 12
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? 12
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 12
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II tria 12
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 12
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 12
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 12
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 12
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 12
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 12
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 12
Gastric cancer: Translating novels concepts into clinical practice 12
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 12
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 12
Second-line treatments: Moving towards an opportunity to improve survival in advanced gastric cancer? 12
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 12
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 12
The Italian Rare Pancreatic Exocrine Cancer Initiative 12
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma 12
Evolution of surgical treatment of colorectal liver metastases in the real world: Single center experience in 1212 cases 12
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 12
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 11
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 11
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 11
Compliance with breast and cervical cancer screening programs in women: results from a population-based study 11
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients 11
GD2 expression in breast cancer 11
Totale 1.508
Categoria #
all - tutte 62.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.704


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021269 0 0 0 5 0 131 41 91 0 0 1 0
2021/2022230 0 1 0 99 7 7 23 44 19 7 6 17
2022/20231.527 738 284 86 8 13 201 41 73 59 6 10 8
2023/2024685 23 38 88 84 43 148 11 61 9 28 46 106
2024/2025616 616 0 0 0 0 0 0 0 0 0 0 0
Totale 3.329